Genomic Health Cuts Q2 Loss in Half as Product Revenue Surges; Shares Jump 15 Percent | GenomeWeb
NEW YORK (GenomeWeb News) – Genomic Health said today net loss fell by nearly half in the second quarter as product revenues quintupled.
The results caused shares in the company to trade up almost 15 percent, or $1.61, at $12.47 in mid-afternoon today.
Receipts for the three months ended June 30 increased to $8.4 million from $1.2 million year over year, Genomic Health said. Oncotype DX product sales to Medicare and privately insured patients accounted for $7.8 million in revenue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.